Hunter syndrome patients continue treatment in Long-Term safety extension trial
NCT ID NCT06031259
First seen Nov 06, 2025 · Last updated May 14, 2026 · Updated 34 times
Summary
This study is a follow-up for people with Hunter syndrome and cognitive problems who completed earlier studies. It aims to check the long-term safety of two medicines given together: idursulfase-IT (injected into the spine) and Elaprase (given through a vein). About 6 children and adults will receive the same treatment they had before, and researchers will watch for any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTER SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital Femme Mere Enfant
Bron, Auvergne-Rhône-Alpes, 02 69229, France
-
Hospital for Sick Children
Toronto, Ontario, M5G1X8, Canada
-
M.A.G.I.C. Clinic
Calgary, Alberta, T2E 7Z4, Canada
-
University of British Columbia
Vancouver, British Columbia, V6T1Z3, Canada
Conditions
Explore the condition pages connected to this study.